The Board of Directors of DexTech proposes a rights issue of approx. MSEK 58.2 in order to further develop the project with multiple myeloma to clinical research and further verify OsteoDex's value
The Board of Directors of DexTech Medical AB ("DexTech" or the "Company") has today decided to convene an Extraordinary General Meeting on November 25, 2021, with a proposal for a new share issue of approximately SEK 58.2 million with preferential rights for existing shareholders (the "Rights Issue"). The public is also given the opportunity to participate. The Rights Issue is covered to approximately 80 percent by subscription commitments and guarantee commitments. Notice of the General Meeting is published through a separate press release. Background and motives for the Rights Issue